Indication: Hematological Malignancies
A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Sub-indication: Peripheral T Cell Lymphoma
Line of Therapy: Relapsed/Refractory
Principal Investigator: Joseph Maly, M.D.Norton Cancer Institute
Sponsor: Verastem, Inc.
Email for more information: Heme-NCIResearch@nortonhealthcare.org